{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T19:11:41Z","timestamp":1725045101884},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ashjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jash.2014.12.012","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T07:17:04Z","timestamp":1421047024000},"page":"257-265","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rationale for a single-pill combination of perindopril arginine and amlodipine besylate"],"prefix":"10.1016","volume":"9","author":[{"given":"William J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2014.12.012_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"16","author":"Weber","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2014.12.012_bib3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the management of arterial hypertension","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jash.2014.12.012_bib4","series-title":"A global brief on hypertension: Silent killer, global public health crisis","first-page":"40","year":"2013"},{"key":"10.1016\/j.jash.2014.12.012_bib5","first-page":"351","article-title":"Racial\/ethnic disparities in the awareness, treatment, and control of hypertension\u2014United States, 2003-2010","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jash.2014.12.012_bib6","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment and control of hypertension: 1998-2008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/HYPERTENSIONAHA.108.119784","article-title":"Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada","volume":"53","author":"Campbell","year":"2009","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jash.2014.12.012_bib9","first-page":"1","article-title":"Deaths: Preliminary data for 2011","volume":"61","author":"Hoyert","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.jash.2014.12.012_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jama.2013.108769","article-title":"Improved blood pressure control associated with a large-scale hypertension program","volume":"310","author":"Jaffe","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema","volume":"124","author":"Makani","year":"2011","journal-title":"Am J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jash.2014.12.012_bib12","first-page":"A22","article-title":"Reduction of amlodipine-associated edema by inhibitors of the renin-angiotensin system: meta-analyses of parallel-group randomized clinical trials","volume":"15","author":"Elliott","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2014.12.012_bib13","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jash.2014.12.012_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS\u2014A Bayesian modeling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comp"},{"key":"10.1016\/j.jash.2014.12.012_bib15","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/sim.1544","article-title":"Bayesian analysis of structural equation models with dichotomous variables","volume":"22","author":"Lee","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jash.2014.12.012_bib16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.12.012_bib17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.12.012_bib18","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial","volume":"51","author":"Ogihara","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.12.012_bib22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2010.186","article-title":"Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial","volume":"34","author":"Narumi","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2014.12.012_bib24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: Nagoya Heart Study","volume":"59","author":"Muramatsu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.12.012_bib25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2014.12.012_bib27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jash.2014.12.012_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/eurheartj\/ehp103","article-title":"The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials","volume":"30","author":"Brugts","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jash.2014.12.012_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib35","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.12.012_bib37","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.295.14.1704","article-title":"Recent trials in hypertension: compelling science or commercial speech?","volume":"295","author":"Psaty","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.12.012_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2014.12.012_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/archinternmed.2011.44","article-title":"Network meta-analysis of heart failure prevention by antihypertensive drugs","volume":"171","author":"Elliott","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2014.12.012_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00129784-200606050-00005","article-title":"The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension","volume":"6","author":"Meurin","year":"2006","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jash.2014.12.012_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ahj.2009.12.042","article-title":"Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post-hoc analysis of the EUROPA study","volume":"59","author":"Bertrand","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2014.12.012_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.113.02252","article-title":"Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial","volume":"63","author":"Chalmers","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.12.012_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/erc.13.42","article-title":"The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review","volume":"11","author":"Ferrari","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jash.2014.12.012_bib44","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jash.2014.12.012_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2014.12.012_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jash.2014.12.012_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.12.012_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jash.2015.01.012","article-title":"Efficacy and safety of perindopril arginine + amlodipine in hypertension","volume":"9","author":"Elliott","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2014.12.012_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/HJH.0000000000000440","article-title":"Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg\/amlodipine 2.5 mg as first-step treatment in hypertension","volume":"33","author":"Laurent","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.12.012_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","article-title":"Comparison of single-pill strategies first line in hypertension: perindopril\/amlodipine versus valsartan\/amlodipine","volume":"33","author":"Mancia","year":"2015","journal-title":"J Hypertens"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114009103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114009103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T10:56:54Z","timestamp":1537959414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171114009103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1933171114009103"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2014.12.012","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for a single-pill combination of perindopril arginine and amlodipine besylate","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2014.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}